v3.25.2
Note 1 - Organization and Nature of Operations (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
May 22, 2025
May 12, 2025
USD ($)
$ / shares
shares
Jul. 15, 2024
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Jun. 20, 2025
Feb. 28, 2025
Jan. 13, 2025
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Common Stock, Shares Authorized (in shares) | shares     30,000,000 60,000,000 60,000,000       60,000,000       60,000,000 60,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares     $ 0.0001 $ 0.0001 $ 0.0001       $ 0.0001         $ 0.0001
Stock, Shares Authorized (in shares) | shares                         70,000,000  
Preferred Stock, Shares Authorized (in shares) | shares       10,000,000 10,000,000       10,000,000       10,000,000 10,000,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest         $ (5,458) $ (4,045) $ (4,220) $ (2,675) $ (9,503) $ (6,895)        
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation                 (4,601) $ (3,639)        
Retained Earnings (Accumulated Deficit)       $ (301,506) (301,506)       (301,506)         $ (292,352)
Working Capital (Deficit)       (2,600) (2,600)       (2,600)          
Cash and Cash Equivalent       $ 838 $ 838       $ 838         $ 2,873
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0001 $ 0.0001       $ 0.0001         $ 0.0001
Series L Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares   2,858                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares   $ 0.5   $ 0.5 $ 0.5       $ 0.5          
Series B Preferred Stock [Member]                            
Preferred Stock, Shares Authorized (in shares) | shares       3,000 3,000       3,000         3,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0001 $ 0.0001       $ 0.0001         $ 0.0001
May 2025 PIPE Financing [Member]                            
Proceeds from Issuance or Sale of Equity   $ 1,500                        
Offering Fees   400                        
Stock Issued During Period, Value, New Issues         $ 2,034                  
Payments of Stock Issuance Costs   $ 400                        
May 2025 PIPE Financing [Member] | Series L Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares   1                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares   $ 0.5                        
May 2025 PIPE Financing [Member] | PIPE Units [Member]                            
Stock Issued During Period, Shares, New Issues (in shares) | shares   1,500                        
Units Issued, Series B Preferred Shares Per Unit   1                        
May 2025 PIPE Financing [Member] | Series B Preferred Stock [Member]                            
Stock Issued During Period, Shares, New Issues (in shares) | shares   1,500                        
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.0001                        
ATM Agreement [Member]                            
Stock Issued During Period, Shares, New Issues (in shares) | shares       4,183,589                    
Stock Issued During Period, Value, New Issues       $ 1,700                    
Payments of Stock Issuance Costs       $ 200                    
Cardionomic's Late-stage Treatment for Acute Decompensated Heart Failure [Member]                            
Debt Instrument, Term (Year) 3 years                          
Reverse Stock Split [Member]                            
Stockholders' Equity Note, Stock Split, Conversion Ratio     10                      
Cardionomix Inc. [Member]                            
Subsidiary, Ownership Percentage, Parent       82.00% 82.00%       82.00%     82.00%    
Cardionomix Inc. [Member] | Chief Executive Officer and Chairman of the Board [Member]                            
Subsidiary, Ownership Percentage, Parent       12.00% 12.00%       12.00%          
Cardionomix Inc. [Member] | Certain Third Parties [Member]                            
Subsidiary, Ownership Percentage, Parent       6.00% 6.00%       6.00%          
KardioNav, Inc. [Member]                            
Subsidiary, Ownership Percentage, Parent       57.00% 57.00%       57.00%   57.00%      
KardioNav, Inc. [Member] | Chief Executive Officer and Chairman of the Board [Member]                            
Subsidiary, Ownership Percentage, Parent       10.00% 10.00%       10.00%          
KardioNav, Inc. [Member] | Certain Third Parties [Member]                            
Subsidiary, Ownership Percentage, Parent       33.00% 33.00%       33.00%          
KardioNav, Inc. [Member] | Chelak iECG, Inc. [Member]                            
Subsidiary, Ownership Percentage, Parent       33.00% 33.00%       33.00%